Want to see HK:6160 full AI Analyst Report?
BeOne Medicines Ltd (6160) Ratios
BeOne Medicines Ltd Ratios
HK:6160's free cash flow for Q2 2026 was $414.83M. For the 2026 fiscal year, HK:6160's free cash flow was decreased by $-47.99M and operating cash flow was $462.82M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.41 | 1.80 | 2.32 | 3.55 | 4.76 |
| Quick Ratio | 3.08 | 1.58 | 2.09 | 3.35 | 4.61 |
| Cash Ratio | 2.51 | 1.19 | 1.75 | 2.63 | 2.74 |
| Solvency Ratio | 0.11 | -0.18 | -0.35 | -0.97 | -0.59 |
| Operating Cash Flow Ratio | 0.62 | -0.06 | -0.64 | -1.02 | -0.81 |
| Short-Term Operating Cash Flow Coverage | 19.71 | -0.17 | -1.68 | -4.55 | -3.04 |
| Net Current Asset Value | $ 2.39B | $ 1.40B | $ 1.94B | $ 3.21B | $ 5.21B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.18 | 0.16 | 0.09 | 0.08 |
| Debt-to-Equity Ratio | 0.25 | 0.32 | 0.26 | 0.14 | 0.11 |
| Debt-to-Capital Ratio | 0.20 | 0.24 | 0.21 | 0.12 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.05 | 0.05 | 0.05 | 0.03 |
| Financial Leverage Ratio | 1.89 | 1.78 | 1.64 | 1.46 | 1.38 |
| Debt Service Coverage Ratio | 3.98 | -0.60 | -1.71 | -5.37 | -3.30 |
| Interest Coverage Ratio | 7.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.06 | 0.05 | 0.05 | 0.02 | 0.03 |
| Interest Debt Per Share | 0.81 | 0.79 | 0.69 | 0.45 | 0.58 |
| Net Debt to EBITDA | -5.93 | 3.90 | 2.00 | 1.90 | 2.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 85.28% | 84.41% | 84.55% | -36.09% | -38.07% |
| EBIT Margin | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
| EBITDA Margin | 11.02% | -10.40% | -45.55% | -121.71% | -118.36% |
| Operating Profit Margin | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
| Pretax Profit Margin | 7.80% | -13.99% | -33.59% | -138.50% | -122.30% |
| Net Profit Margin | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% |
| Continuous Operations Profit Margin | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% |
| Net Income Per EBT | 68.83% | 120.97% | 106.77% | 102.18% | 101.34% |
| EBT Per EBIT | 93.23% | 93.81% | 68.38% | 109.58% | 99.99% |
| Return on Assets (ROA) | 3.49% | -10.89% | -15.19% | -31.41% | -16.86% |
| Return on Equity (ROE) | 6.59% | -19.35% | -24.93% | -45.71% | -23.35% |
| Return on Capital Employed (ROCE) | 6.99% | -15.33% | -30.23% | -36.44% | -20.42% |
| Return on Invested Capital (ROIC) | 4.76% | -12.42% | -25.67% | -34.00% | -19.19% |
| Return on Tangible Assets | 3.52% | -11.13% | -15.34% | -33.06% | -17.07% |
| Earnings Yield | 0.88% | -3.35% | -4.80% | -8.70% | -5.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.03 | 5.37 | 6.21 | 7.12 | 2.35 |
| Payables Turnover | 1.64 | 1.47 | 1.21 | 6.54 | 9.67 |
| Inventory Turnover | 1.30 | 1.20 | 0.91 | 6.82 | 6.69 |
| Fixed Asset Turnover | 2.99 | 2.30 | 1.73 | 1.67 | 1.71 |
| Asset Turnover | 0.65 | 0.64 | 0.42 | 0.22 | 0.14 |
| Working Capital Turnover Ratio | 1.73 | 1.83 | 0.80 | 0.29 | 0.24 |
| Cash Conversion Cycle | 120.34 | 123.22 | 155.81 | 48.94 | 171.97 |
| Days of Sales Outstanding | 60.49 | 67.93 | 58.77 | 51.29 | 155.20 |
| Days of Inventory Outstanding | 281.79 | 304.11 | 399.78 | 53.48 | 54.53 |
| Days of Payables Outstanding | 221.94 | 248.82 | 302.74 | 55.84 | 37.76 |
| Operating Cycle | 342.28 | 372.04 | 458.55 | 104.78 | 209.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.80 | -0.10 | -0.85 | -1.12 | -1.08 |
| Free Cash Flow Per Share | 0.67 | -0.49 | -1.29 | -1.47 | -1.34 |
| Dividend Paid and CapEx Coverage Ratio | 6.07 | -0.27 | -1.94 | -4.60 | -4.94 |
| Capital Expenditure Coverage Ratio | 6.07 | -0.27 | -1.94 | -4.60 | -4.94 |
| Operating Cash Flow Coverage Ratio | 1.03 | -0.13 | -1.24 | -2.51 | -1.87 |
| Operating Cash Flow to Sales Ratio | 0.21 | -0.04 | -0.47 | -1.06 | -1.10 |
| Free Cash Flow Yield | 2.89% | -3.48% | -9.54% | -8.53% | -6.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 115.16 | -29.90 | -20.84 | -11.49 | -17.08 |
| Price-to-Sales (P/S) Ratio | 6.10 | 5.05 | 7.47 | 16.27 | 21.17 |
| Price-to-Book (P/B) Ratio | 7.49 | 5.77 | 5.20 | 5.25 | 3.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 34.63 | -28.72 | -10.48 | -11.72 | -15.43 |
| Price-to-Operating Cash Flow Ratio | 28.92 | -136.77 | -15.88 | -15.39 | -19.17 |
| Price-to-Earnings Growth (PEG) Ratio | -0.81 | 1.08 | 0.37 | -0.42 | 1.08 |
| Enterprise Value Multiple | 49.45 | -44.61 | -14.41 | -11.47 | -15.24 |
| Enterprise Value | 29.16B | 17.69B | 16.14B | 19.76B | 21.22B |
| EV to EBITDA | 49.45 | -44.61 | -14.41 | -11.47 | -15.24 |
| EV to Sales | 5.45 | 4.64 | 6.56 | 13.96 | 18.04 |
| EV to Free Cash Flow | 30.92 | -26.41 | -9.20 | -10.05 | -13.15 |
| EV to Operating Cash Flow | 25.82 | -125.76 | -13.94 | -13.20 | -16.34 |
| Tangible Book Value Per Share | 3.05 | 2.34 | 2.56 | 3.03 | 5.09 |
| Shareholders’ Equity Per Share | 3.08 | 2.43 | 2.61 | 3.27 | 5.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.31 | -0.21 | -0.07 | -0.02 | -0.01 |
| Revenue Per Share | 3.77 | 2.78 | 1.81 | 1.06 | 0.98 |
| Net Income Per Share | 0.20 | -0.47 | -0.65 | -1.49 | -1.21 |
| Tax Burden | 0.69 | 1.21 | 1.07 | 1.02 | 1.01 |
| Interest Burden | 0.93 | 0.94 | 0.68 | 1.10 | 1.00 |
| Research & Development to Revenue | 0.39 | 0.51 | 0.72 | 1.16 | 1.24 |
| SG&A to Revenue | 0.38 | 0.48 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.10 | 0.12 | 0.15 | 0.21 | 0.20 |
| Income Quality | 3.93 | 0.22 | 1.31 | 0.75 | 0.89 |
Currency in USD
